AI Startup EnsoData Secures $20M to Revolutionize Sleep Disorder Diagnosis
Madison, Wisconsin – June 26, 2025 – Access to sleep medicine remains a critical global health challenge, with an estimated 80% of individuals suffering from sleep apnea going undiagnosed [[1]]. Now, AI is stepping in to bridge this gap. EnsoData, a Wisconsin-based startup, announced today it has raised $20 million in Series B funding, led by Questa Capital, bringing its total funding to over $50 million.
Founded in 2015,EnsoData is leveraging the power of artificial intelligence to dramatically improve the speed and accuracy of sleep disorder diagnosis. The company’s platform analyzes data from polysomnography studies and home sleep apnea tests,identifying key events like apneas,hypopneas,and arousals with unprecedented efficiency.
“EnsoData’s technology saves clinicians time and enables private sleep labs and healthcare systems to provide patients with fast and accurate diagnoses, treatment and results – while also generating more revenue by reducing the amount of time clinicians spend analyzing data by nearly 70%,” stated CEO Justin Mortara.
Traditionally, sleep study analysis is a manual, time-consuming process, often taking hours per study and subject to scorer variability. EnsoData’s AI automates this process, generating comprehensive sleep reports in minutes, freeing up clinicians to focus on patient care and interpretation of results [[2]]. This innovation promises to significantly improve access to vital sleep medicine and address a widespread, often hidden, health crisis.
Keywords: AI, Sleep Apnea, Sleep Disorders, Healthcare Technology, Digital Health, EnsoData, Funding, Investment, Polysomnography, Diagnosis.
Call to Action: Learn more about EnsoData and the future of sleep medicine at https://www.ensodata.com/.
